Compare RCKY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKY | SLN |
|---|---|---|
| Founded | 1932 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 236.2M |
| IPO Year | 1996 | N/A |
| Metric | RCKY | SLN |
|---|---|---|
| Price | $44.67 | $5.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $39.67 |
| AVG Volume (30 Days) | 41.6K | ★ 153.4K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 7.80 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $270,408,000.00 | N/A |
| Revenue This Year | $7.09 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | $22.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.97 | $1.97 |
| 52 Week High | $48.70 | $7.78 |
| Indicator | RCKY | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 77.99 | 57.17 |
| Support Level | $27.77 | $5.07 |
| Resistance Level | N/A | $6.04 |
| Average True Range (ATR) | 1.60 | 0.41 |
| MACD | 1.45 | 0.13 |
| Stochastic Oscillator | 82.32 | 82.77 |
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.